A vs ADM Stock Comparison

Scores Breakdown

Metric	A	ADM
📈 Growth	18/30	26/30
💰 Profitability	16/20	7/20
🏦 Financial Health	7/20	16/20
💵 Valuation	9/20	12/20
⚠️ Risk (lower is better)	7/10	6/10
Overall Score	53/100	65/100

Side-by-Side Summaries

A Analysis	ADM Analysis
📈 Growth & Financial Trajectory Over eight quarters, Revenues rose from about $1.66B to $1.84B, a positive trend, with a mid-2025 dip. Net income fluctuated from $308M–$434M, ending near $339M in 2026 Q2. The sequence shows top-line resilience but earnings volatility, implying improving mix or cost management but not a steady uplift in profitability. 💰 Margins & Cash Flow Gross Margin is generally in the mid-50s percentile, peaking around 63% in 2024 Q2 and typical ~50–55% in other quarters. Operating Margin has run in the high-teens to low-20s percent range on Revenues of ~$1.6–$1.8B. Operating cash flow remains positive across quarters (roughly $0.27–$0.55B), while investing cash flow is negative (capital outlays), and financing cash flow is often negative, reflecting debt/return actions. 🛡️ Balance Sheet & Liquidity Total Assets (~~$11–$13B) exceed Liabilities (~~$4.8–$6B) with Equity frequently negative, signaling balance-sheet rehabilitation needs. Current assets vs current liabilities suggests solid liquidity (working capital positive); long-term debt remains a meaningful load but generally manageable within cash flows. ⚠️ Key Drivers & Risks Drivers: Life sciences capex & instrument upgrades; continued demand for laboratory testing and automation. Risks: Earnings volatility from cyclic lab-spend; structural negative equity raises valuation sensitivity and balance-sheet risk.	📈 Growth & Financial Trajectory Over 8 quarters, ADM's Revenues moved in a narrow band around 19.9–20.5B, ending near 20.49B in Q1 2026 vs 19.94B at the start—a modest +2.9% gain. Net income progressed from about $18M in 2024 Q2 to $303M in 2026 Q1, with a peak of $567M in 2024 Q4, signaling improving profitability despite quarterly volatility. 💰 Margins & Cash Flow Gross margin remained steady at about 6.3%–6.8% across the period; operating margin hovered around 2%–3%. Operating cash flow was positive in most quarters (e.g., +4.30B in 2025 Q3, +1.81B in 2025 Q2, +0.15B in 2026 Q1), while investing cash flow was consistently negative, and financing activity varied, reflecting ongoing capital allocation. 🛡️ Balance Sheet & Liquidity Assets run around $52–53B with current assets about $26.6–29B and current liabilities near $18.0–19.6B, giving a healthy current ratio of roughly 1.3–1.5. Debt metrics show long-term debt around $7.6–8.3B and total liabilities around $29–33B, with equity in the low- to mid-$22B range, indicating solid balance-sheet resilience. ⚠️ Key Drivers & Risks Drivers: Commodity cycle for grains/oilseeds; global demand for ADM's processing and ingredients Risks: Commodity price volatility and cyclicality; macroeconomic sensitivity and valuation risk

A Analysis

ADM Analysis

📈 Growth & Financial Trajectory

Over eight quarters, Revenues rose from about $1.66B to $1.84B, a positive trend, with a mid-2025 dip. Net income fluctuated from $308M–$434M, ending near $339M in 2026 Q2. The sequence shows top-line resilience but earnings volatility, implying improving mix or cost management but not a steady uplift in profitability.

💰 Margins & Cash Flow

Gross Margin is generally in the mid-50s percentile, peaking around 63% in 2024 Q2 and typical ~50–55% in other quarters.
Operating Margin has run in the high-teens to low-20s percent range on Revenues of ~$1.6–$1.8B.
Operating cash flow remains positive across quarters (roughly $0.27–$0.55B), while investing cash flow is negative (capital outlays), and financing cash flow is often negative, reflecting debt/return actions.

🛡️ Balance Sheet & Liquidity

Total Assets (~~$11–$13B) exceed Liabilities (~~$4.8–$6B) with Equity frequently negative, signaling balance-sheet rehabilitation needs. Current assets vs current liabilities suggests solid liquidity (working capital positive); long-term debt remains a meaningful load but generally manageable within cash flows.

⚠️ Key Drivers & Risks

Drivers: Life sciences capex & instrument upgrades; continued demand for laboratory testing and automation.
Risks: Earnings volatility from cyclic lab-spend; structural negative equity raises valuation sensitivity and balance-sheet risk.

📈 Growth & Financial Trajectory

Over 8 quarters, ADM's Revenues moved in a narrow band around 19.9–20.5B, ending near 20.49B in Q1 2026 vs 19.94B at the start—a modest +2.9% gain. Net income progressed from about $18M in 2024 Q2 to $303M in 2026 Q1, with a peak of $567M in 2024 Q4, signaling improving profitability despite quarterly volatility.

💰 Margins & Cash Flow

Gross margin remained steady at about 6.3%–6.8% across the period; operating margin hovered around 2%–3%. Operating cash flow was positive in most quarters (e.g., +4.30B in 2025 Q3, +1.81B in 2025 Q2, +0.15B in 2026 Q1), while investing cash flow was consistently negative, and financing activity varied, reflecting ongoing capital allocation.

🛡️ Balance Sheet & Liquidity

Assets run around $52–53B with current assets about $26.6–29B and current liabilities near $18.0–19.6B, giving a healthy current ratio of roughly 1.3–1.5. Debt metrics show long-term debt around $7.6–8.3B and total liabilities around $29–33B, with equity in the low- to mid-$22B range, indicating solid balance-sheet resilience.

⚠️ Key Drivers & Risks

Drivers: Commodity cycle for grains/oilseeds; global demand for ADM's processing and ingredients
Risks: Commodity price volatility and cyclicality; macroeconomic sensitivity and valuation risk

Similar Companies

AMAT Score: 80 AME Score: 81 ANET Score: 84 GOOGL Score: 78 TMO Score: 75 WAT Score: 78

Top Rated Companies

View Top 20 →

MU "MICRON TECHNOLOGY INC"

AVGO "Broadcom Inc."

KMI "KINDER MORGAN, INC."

MNST "Monster Beverage Corp"

NEM "NEWMONT Corp /DE/"